Skip to main content
. 2021 Oct 21;13(21):5277. doi: 10.3390/cancers13215277

Table 2.

Frequency of ir thyroid disorders according to recent reviews.

Ir Hypothyroidism Ir Hyperthyroidism
Ref. Anti-CTL-A4 Anti-PD-1/PDL-1 Combo or Sequential Regimens Anti-CTL-A4 Anti-PD-1/PDL-1 Combo or Sequential Regimens
[36] 2.5–5.2 3.9–8.5 10.2–16.4 0.2–1.7 0.6–3.7 8.0–11.1
[38] 2/29 cases 16/29 cases 11/29 cases
(9/29 cases for sequential
2/29 for combo) 		IPI: 4/6 cases NIVO: 1/6 cases IPI + anti-PD-1/anti-PDL-1: 1/6 cases
[39] IPI: 6 NS IPI + NIVO: 22 NS NS NS
[40] TREME: 2.3 5.9 13.9 TREME: 2.6 3.3 8
[41] 4.3–11.0 a
5.2–5.9 b 		5.9 22 a
17 b 		2 1–4.7 10
[42] IPI:
Any G: 5
G 3–4: 0		 NIVO: Any G: 11
G 3–4: 0		 NIVO + IPI:
Any G: 17
G 3–4: <1		 IPI:
Any G: 1
G 3–4: 0		 NIVO:
Any G: 4
G 3–4: 0		 NIVO + IPI:
Any G: 11
G 3–4: 1
[43] NS PEM
melanoma: 8.7
NIVO
melanoma:
8.6
NIVO
SC- NSCLC: 4
NIVO
NS- NSCLC: 6.6		 NS NS PEM
melanoma:
3.2
NIVO
melanoma:
4.2
NIVO
NS- NSCLC:1.4		 NIVO + IPI: 9.9
[44] IPI: 1.5–6.8
TREME: 2.3 		NIVO: 9–10.8
PEM: 7–9.1
AVE: 5
ATE: 2.5–4.2
DUVRA: 5.5–9.6		 NIVO + IPI: 4–27
PEM + IPI: 6–13.6
DUVRA + TREME: 5.9 		IPI: 4
TREME: 0–3
 NIVO: 2.7
PEM: 3.4–7.8
AVE: 0.4
ATE: 0.6–1.1
DUVRA: 4.9–5.7		 NIVO + IPI: 4.3–14
PEM + IPI: 4.5–6
DUVRA + TREME: NR
[45] IPI: 1.5–13.3
TREME: 2–3		 Anti-PD-1: 2–3
Anti-PD-L1: 3		 NS TREME: <1–2.5 Anti-PD-1: <1 NS
[37] Any ir thyroid disorder
Anti-CTLA-4 Anti-PD-1/anti-PDL-1 Combo or sequential
IPI: 4.7 (range 2.0–10.4) ATE: 22.2
NIVO: 8.8 (range 2.0–10.4)

  • melanoma: 11.4

  • other solid organ cancers: 5.5

PEMBRO: 15.6 (range: 10.6–27.4)		 IPI + NIVO: 16.0

  • melanoma (24.9)

  • lung cancer (11.6)

  • renal cell cancer (15.5)

IPI then NIVO: 15.1

All percentages represent incidence (95% confidence intervals), except the percentages in [41] that represent the prevalence. a Secondary hypothyroidism. b Primary hypothyroidism. Abbreviations: anti-CTLA-4, antibodies against cytotoxic T-lymphocyte antigen 4, anti-PD-1, antibodies against programmed cell death protein-1; anti-PD-L1, antibodies against PD-1 ligand molecule; ATE, atezolizumab; AVE, avelumab; DUVRA, durvalumab; IPI, ipilimumab; NIVO, nivolumab; NR, not reported; NS, not studied; NS-NSCLC, non-squamous non-small-cell lung cancer; Ref, reference; SC-NSCLC, squamous-cell non-small-cell lung cancer.